Industry in brief | Royal DSM, Flarin

Industry in brief | Royal DSM, Flarin

6 April 2021 - Deborah Wilkes

Royal DSM is investing USD100 million in a new personalised nutrition company called Hologram Sciences and Flarin has completed a second fundraising round.

DSM backs Hologram Sciences

Hologram Sciences – a new company backed by USD100 million in funding from ingredients company Royal DSM – wants to “disrupt the nutrition marketplace by offering consumer-facing personalised solutions”. The company's slogan is "reimaging the future of nutrition".

DSM said Hologram Sciences was a consumer-facing company that aimed to “create brands targeting various health conditions”.

Hologram Sciences would provide consumers with “more holistic solutions to manage their health”, said DSM, by “combining health diagnostics, digital coaching and personalised nutrition”.

The company’s first solution will be a “rapid immunity concept addressing the current acute concern over the ongoing COVID-19 pandemic”.

Hologram Sciences aims to take personalised nutrition to a new level for consumers and DSM’s customers. “As solutions are validated in-market, they will be available to DSM customers,” said DSM. “Hologram will also work to incubate products with DSM customers and partners.”

Flarin raises funds

Flarin Holdings said it had completed a second fundraising round to support the commercial development of Flarin, its lipid-formulated ibuprofen medicine.

Managing director Andrew Macmillen said the UK-based company planned to drive further growth in its home market and accelerate international expansion. Flarin is currently only available in the UK.

“These new funds give Flarin greater ability to increase investment in marketing in the UK as well as continuing to progress regulatory submissions and partnerships in other countries including the US,” commented Macmillen.

Flarin was launched as a pharmacy medicine in the UK in early 2018. A general-sale list version called Flarin Joint & Muscular Pain Relief was introduced in 2020.

Marketing for Flarin features the claim “no other ibuprofen is proven to be more effective for joint pain” and highlights that the lipid formulation “helps shield your stomach from damage”.

The latest fundraising round was led by private-equity firm IW Capital which invested in the first fundraising round in October 2019.

Click tags below for more information on topics:


Back to Industry News

Share this page: